Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier:
NCT01803087
First received: October 4, 2012
Last updated: March 1, 2013
Last verified: March 2013
  Purpose

This clinical pharmacology want to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products; this will be additionally compared to the systemic exposure in adults without the spacer device.


Condition Intervention Phase
Asthma
Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
Drug: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
Drug: BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
Drug: CHF 1535 100/6 pMDI (Foster®) (CTR)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.

Resource links provided by NLM:


Further study details as provided by Chiesi Farmaceutici S.p.A.:

Primary Outcome Measures:
  • AUC0-t of B17MP CHF 1535 100/6 pMDI with and without spacer vs free combination of BDP pMDI and formoterol pMDI [ Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation. ] [ Designated as safety issue: No ]
    In adolescents, the systemic exposure of B17MP as AUC0-t, after inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) vs already licensed free combination of BDP pMDI and formoterol pMDI without spacer.


Secondary Outcome Measures:
  • AUC0-t, AUC0-inf, Cmax, tmax and t½ for BDP and formoterol [ Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation. ] [ Designated as safety issue: No ]
    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.

  • AUC0-0.5h, AUC0-inf, Cmax, tmax and t½ for B17MP [ Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation. ] [ Designated as safety issue: No ]
    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.

  • plasma glucose and plasma potassium AUC0-t; Cmin; Tmin; Cmax; Tmax [ Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation. ] [ Designated as safety issue: No ]
    In adolescents, after inhalation of CHF 1535 100/6 pMDI with and without spacer (AeroChamber Plus™)vs fre combination

  • Heart rate as AUC0-8h of CHF 1535 100/6 pMDI [ Time Frame: pre-dose (within 5 min from dosing), 5 min; 10 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation. ] [ Designated as safety issue: No ]
    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs free combination

  • FEV1; time everaged FEV1 value AUC0-8h; peak FEV1 [ Time Frame: pre-dose; 30 min; 1, 2, 4, 6 and 8 hr after inhalation. ] [ Designated as safety issue: No ]
    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.


Enrollment: 60
Study Start Date: February 2012
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CHF 1535 100/6 pMDI (Foster®) TEST 1
Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
Active Comparator: CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).
CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
Drug: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
Active Comparator: (Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)
BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
Drug: BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
Other Name: Free combination of BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) in adolescents (REF)
Active Comparator: CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Drug: CHF 1535 100/6 pMDI (Foster®) (CTR)
Other Name: CHF 1535 100/6 pMDI (Foster®) in adults (CTR)

Detailed Description:

The proposed clinical pharmacology study is aimed to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI (to reach a total dose of BDP 400 µg and formoterol 24 µg) with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products (to reach the same total dose of BDP and formoterol) in adolescent asthmatic patients. The systemic exposure to BDP/B17MP and formoterol after inhalation of CHF 1535 pMDI in adolescents will be additionally compared to the systemic exposure in adults without the spacer device.

The chosen doses correspond to the maximum daily dose of the two components administered as fixed combination.

  Eligibility

Ages Eligible for Study:   12 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

- Inclusion criteria

Patients will be enrolled if they meet all of the following criteria:

  1. Male and female adolescents, aged ≥ 12 and < 18 years at the time of Screening Visit or male and female adults, aged ≥ 18 and ≤ 65 years at the time of Screening Visit.
  2. Written informed consent obtained by the patient in case of adult patients and by parents/legal representative and by the minor (according to local regulation).
  3. A diagnosis of asthma as defined in the GINA guidelines (updated 2010) 6 months before the screening visit.
  4. Male/female adolescent and adult patients with asthma stable enough, according to GINA guidelines (updated 2010) and based on the Investigator's opinion, to allow a wash out period from inhaled BDP of 2 days before each single day study treatments and any ICS other than BDP of 1 day before each single day study treatments.
  5. Male/female adolescents and adults asthmatic patients already treated with ICS or ICS/long-acting inhaled β2-agonists or using short-acting inhaled β2-agonists as reliever to control asthma symptoms.
  6. Adolescents and adults with a forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred) after withholding short acting β2-agonist treatment for a minimum of 6 h prior to screening or 24 hours in case of long acting β2-agonist.
  7. Non- or ex-smokers who smoked less than 5 pack-years (e.g. < 20 cigarettes per day for 5 years) and stopped smoking for at least 1 year.
  8. A cooperative attitude and ability to be trained about the proper use of pMDI with and without a spacer device and compliant to study procedures.
  9. Body mass index (BMI) ≥18.5 and ≤ 32 kg/m2

    • Exclusion criteria

Patients will not be enrolled if one or more of the following criteria are present:

  1. Pregnant or breast-feeding female patients. Sexually active female not using efficient contraception throughout the entire study period (e.g. oestro-progestatives, condoms, intrauterine devices). A urinary pregnancy test will be performed at screening and treatment visits (mandatory in the adult population and at discretion of the investigator in the adolescent population) in women of childbearing potential;
  2. Having received an investigational drug within 2 months before the screening visit (Visit 1).
  3. Diagnosis of COPD, in the adult patients, as defined by the current GOLD guidelines (updated 2010).
  4. Known hypersensitivity to the active treatments.
  5. Inability to perform the required breathing technique and blood sampling.
  6. Hospitalization due to exacerbation of asthma within 1 month prior to the screening visit.
  7. Lower respiratory tract infection within 1 month prior to screening visit.
  8. Obesity, i.e. > 97% weight percentile by local standards.
  9. Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, that may interfere with patient's safety, compliance, or study evaluations, according to the Investigator's opinion;
  10. History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements;
  11. Treatment with a xanthine derivative (e.g. theophylline) formulations in the 4 weeks prior to screening;
  12. Blood donation (450 mL or more) (for the adult population) or significant blood loss in the 12 weeks before the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01803087

Locations
Poland
Uniwersytecki Szpital Kliniczny nr 1
Lodz, Poland, 90153
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
  More Information

No publications provided

Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT01803087     History of Changes
Other Study ID Numbers: CCD-1104-PR-0062
Study First Received: October 4, 2012
Last Updated: March 1, 2013
Health Authority: Poland: National Institute of Medicines

Keywords provided by Chiesi Farmaceutici S.p.A.:
adolescents
adults

Additional relevant MeSH terms:
Formoterol
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014